{"id":5796,"date":"2023-05-24T09:24:57","date_gmt":"2023-05-24T07:24:57","guid":{"rendered":"https:\/\/p664637.webspaceconfig.de\/?post_type=izb-biotech-news&p=5796"},"modified":"2026-07-22T14:56:55","modified_gmt":"2026-07-22T12:56:55","slug":"preclinical-efficacy-and-safety-data-for-vigenerons-innovative-approach-to-the-treatment-of-retinitis-pigmentosa-innovations-und-gruenderzentrum-biotechnologie-izb","status":"publish","type":"izb-biotech-news","link":"https:\/\/p664637.webspaceconfig.de\/en\/izb-biotech-news\/preclinical-efficacy-and-safety-data-for-vigenerons-innovative-approach-to-the-treatment-of-retinitis-pigmentosa-innovations-und-gruenderzentrum-biotechnologie-izb\/","title":{"rendered":"Preclinical efficacy and safety data for ViGeneron\u2019s innovative approach to the treatment of Retinitis Pigmentosa"},"content":{"rendered":"","protected":false},"excerpt":{"rendered":"

The company\u2019s lead program VG901 is the first gene therapy targeting CNGA1 mutation of this hereditary eye disease.<\/p>\n","protected":false},"featured_media":5795,"parent":0,"menu_order":0,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[81],"tags":[],"class_list":["post-5796","izb-biotech-news","type-izb-biotech-news","status-publish","format-standard","has-post-thumbnail","hentry","category-izb-biotech-news-en"],"acf":[],"acf_migration":{"izb_related_company":"6292"},"wpml_migration":{"language_code":"en","source_language_code":"de","trid":"29536"},"yoast_migration":{"_yoast_wpseo_title":"Preclinical efficacy and safety data for ViGeneron\u2019s innovative approach to the treatment of Retinitis Pigmentosa - Innovations- und Gr\u00fcnderzentrum Biotechnologie IZB","_yoast_wpseo_metadesc":"The company\u2019s lead program VG901 is the first gene therapy targeting CNGA1 mutation of this hereditary eye disease."},"permalink_migration":{"custom_uri":"izb-biotech-news\/preclinical-efficacy-and-safety-data-for-vigenerons-innovative-approach-to-the-treatment-of-retinitis-pigmentosa-innovations-und-gruenderzentrum-biotechnologie-izb"},"yoast_head":"\nPreclinical efficacy and safety data for ViGeneron\u2019s innovative approach to the treatment of Retinitis Pigmentosa - Innovations- und Gr\u00fcnderzentrum Biotechnologie IZB<\/title>\n<meta name=\"description\" content=\"The company\u2019s lead program VG901 is the first gene therapy targeting CNGA1 mutation of this hereditary eye disease.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/p664637.webspaceconfig.de\/en\/izb-biotech-news\/preclinical-efficacy-and-safety-data-for-vigenerons-innovative-approach-to-the-treatment-of-retinitis-pigmentosa-innovations-und-gruenderzentrum-biotechnologie-izb\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Preclinical efficacy and safety data for ViGeneron\u2019s innovative approach to the treatment of Retinitis Pigmentosa - Innovations- und Gr\u00fcnderzentrum Biotechnologie IZB\" \/>\n<meta property=\"og:description\" content=\"The company\u2019s lead program VG901 is the first gene therapy targeting CNGA1 mutation of this hereditary eye disease.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/p664637.webspaceconfig.de\/en\/izb-biotech-news\/preclinical-efficacy-and-safety-data-for-vigenerons-innovative-approach-to-the-treatment-of-retinitis-pigmentosa-innovations-und-gruenderzentrum-biotechnologie-izb\/\" \/>\n<meta property=\"og:site_name\" content=\"IZB Innovations- und Gr\u00fcnderzentrum Biotechnologie.\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-22T12:56:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/p664637.webspaceconfig.de\/wp-content\/uploads\/2026\/07\/ViGeneron_Retinitis_600x383-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"600\" \/>\n\t<meta property=\"og:image:height\" content=\"383\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/p664637.webspaceconfig.de\\\/en\\\/izb-biotech-news\\\/preclinical-efficacy-and-safety-data-for-vigenerons-innovative-approach-to-the-treatment-of-retinitis-pigmentosa-innovations-und-gruenderzentrum-biotechnologie-izb\\\/\",\"url\":\"https:\\\/\\\/p664637.webspaceconfig.de\\\/en\\\/izb-biotech-news\\\/preclinical-efficacy-and-safety-data-for-vigenerons-innovative-approach-to-the-treatment-of-retinitis-pigmentosa-innovations-und-gruenderzentrum-biotechnologie-izb\\\/\",\"name\":\"Preclinical efficacy and safety data for ViGeneron\u2019s innovative approach to the treatment of Retinitis Pigmentosa - Innovations- und Gr\u00fcnderzentrum Biotechnologie IZB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/p664637.webspaceconfig.de\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/p664637.webspaceconfig.de\\\/en\\\/izb-biotech-news\\\/preclinical-efficacy-and-safety-data-for-vigenerons-innovative-approach-to-the-treatment-of-retinitis-pigmentosa-innovations-und-gruenderzentrum-biotechnologie-izb\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/p664637.webspaceconfig.de\\\/en\\\/izb-biotech-news\\\/preclinical-efficacy-and-safety-data-for-vigenerons-innovative-approach-to-the-treatment-of-retinitis-pigmentosa-innovations-und-gruenderzentrum-biotechnologie-izb\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/p664637.webspaceconfig.de\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/ViGeneron_Retinitis_600x383-1.jpg\",\"datePublished\":\"2023-05-24T07:24:57+00:00\",\"dateModified\":\"2026-07-22T12:56:55+00:00\",\"description\":\"The company\u2019s lead program VG901 is the first gene therapy targeting CNGA1 mutation of this hereditary eye disease.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/p664637.webspaceconfig.de\\\/en\\\/izb-biotech-news\\\/preclinical-efficacy-and-safety-data-for-vigenerons-innovative-approach-to-the-treatment-of-retinitis-pigmentosa-innovations-und-gruenderzentrum-biotechnologie-izb\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/p664637.webspaceconfig.de\\\/en\\\/izb-biotech-news\\\/preclinical-efficacy-and-safety-data-for-vigenerons-innovative-approach-to-the-treatment-of-retinitis-pigmentosa-innovations-und-gruenderzentrum-biotechnologie-izb\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/p664637.webspaceconfig.de\\\/en\\\/izb-biotech-news\\\/preclinical-efficacy-and-safety-data-for-vigenerons-innovative-approach-to-the-treatment-of-retinitis-pigmentosa-innovations-und-gruenderzentrum-biotechnologie-izb\\\/#primaryimage\",\"url\":\"https:\\\/\\\/p664637.webspaceconfig.de\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/ViGeneron_Retinitis_600x383-1.jpg\",\"contentUrl\":\"https:\\\/\\\/p664637.webspaceconfig.de\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/ViGeneron_Retinitis_600x383-1.jpg\",\"width\":600,\"height\":383,\"caption\":\"Retinitis pigmentosa, eine genetische Augenkrankheit. Die 3D-Abbildung zeigt die Pigmentablagerungen in der Netzhaut, die abgeschw\u00e4chten Blutgef\u00e4\u00dfe, die pigment\u00e4ren Knochenmarkstifte und das wachsartige Aussehen der optischen Scheibe.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/p664637.webspaceconfig.de\\\/en\\\/izb-biotech-news\\\/preclinical-efficacy-and-safety-data-for-vigenerons-innovative-approach-to-the-treatment-of-retinitis-pigmentosa-innovations-und-gruenderzentrum-biotechnologie-izb\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/p664637.webspaceconfig.de\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"IZB Biotech News\",\"item\":\"https:\\\/\\\/p664637.webspaceconfig.de\\\/izb-biotech-news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Preclinical efficacy and safety data for ViGeneron\u2019s innovative approach to the treatment of Retinitis Pigmentosa\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/p664637.webspaceconfig.de\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/p664637.webspaceconfig.de\\\/en\\\/\",\"name\":\"IZB Innovations- und Gr\u00fcnderzentrum Biotechnologie.\",\"description\":\"Der Ort f\u00fcr Biotech-Start-ups in M\u00fcnchen: Labore, B\u00fcror\u00e4ume, Netzwerk!\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/p664637.webspaceconfig.de\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Preclinical efficacy and safety data for ViGeneron\u2019s innovative approach to the treatment of Retinitis Pigmentosa - Innovations- und Gr\u00fcnderzentrum Biotechnologie IZB","description":"The company\u2019s lead program VG901 is the first gene therapy targeting CNGA1 mutation of this hereditary eye disease.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/p664637.webspaceconfig.de\/en\/izb-biotech-news\/preclinical-efficacy-and-safety-data-for-vigenerons-innovative-approach-to-the-treatment-of-retinitis-pigmentosa-innovations-und-gruenderzentrum-biotechnologie-izb\/","og_locale":"en_US","og_type":"article","og_title":"Preclinical efficacy and safety data for ViGeneron\u2019s innovative approach to the treatment of Retinitis Pigmentosa - Innovations- und Gr\u00fcnderzentrum Biotechnologie IZB","og_description":"The company\u2019s lead program VG901 is the first gene therapy targeting CNGA1 mutation of this hereditary eye disease.","og_url":"https:\/\/p664637.webspaceconfig.de\/en\/izb-biotech-news\/preclinical-efficacy-and-safety-data-for-vigenerons-innovative-approach-to-the-treatment-of-retinitis-pigmentosa-innovations-und-gruenderzentrum-biotechnologie-izb\/","og_site_name":"IZB Innovations- und Gr\u00fcnderzentrum Biotechnologie.","article_modified_time":"2026-07-22T12:56:55+00:00","og_image":[{"width":600,"height":383,"url":"https:\/\/p664637.webspaceconfig.de\/wp-content\/uploads\/2026\/07\/ViGeneron_Retinitis_600x383-1.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/p664637.webspaceconfig.de\/en\/izb-biotech-news\/preclinical-efficacy-and-safety-data-for-vigenerons-innovative-approach-to-the-treatment-of-retinitis-pigmentosa-innovations-und-gruenderzentrum-biotechnologie-izb\/","url":"https:\/\/p664637.webspaceconfig.de\/en\/izb-biotech-news\/preclinical-efficacy-and-safety-data-for-vigenerons-innovative-approach-to-the-treatment-of-retinitis-pigmentosa-innovations-und-gruenderzentrum-biotechnologie-izb\/","name":"Preclinical efficacy and safety data for ViGeneron\u2019s innovative approach to the treatment of Retinitis Pigmentosa - Innovations- und Gr\u00fcnderzentrum Biotechnologie IZB","isPartOf":{"@id":"https:\/\/p664637.webspaceconfig.de\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/p664637.webspaceconfig.de\/en\/izb-biotech-news\/preclinical-efficacy-and-safety-data-for-vigenerons-innovative-approach-to-the-treatment-of-retinitis-pigmentosa-innovations-und-gruenderzentrum-biotechnologie-izb\/#primaryimage"},"image":{"@id":"https:\/\/p664637.webspaceconfig.de\/en\/izb-biotech-news\/preclinical-efficacy-and-safety-data-for-vigenerons-innovative-approach-to-the-treatment-of-retinitis-pigmentosa-innovations-und-gruenderzentrum-biotechnologie-izb\/#primaryimage"},"thumbnailUrl":"https:\/\/p664637.webspaceconfig.de\/wp-content\/uploads\/2026\/07\/ViGeneron_Retinitis_600x383-1.jpg","datePublished":"2023-05-24T07:24:57+00:00","dateModified":"2026-07-22T12:56:55+00:00","description":"The company\u2019s lead program VG901 is the first gene therapy targeting CNGA1 mutation of this hereditary eye disease.","breadcrumb":{"@id":"https:\/\/p664637.webspaceconfig.de\/en\/izb-biotech-news\/preclinical-efficacy-and-safety-data-for-vigenerons-innovative-approach-to-the-treatment-of-retinitis-pigmentosa-innovations-und-gruenderzentrum-biotechnologie-izb\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/p664637.webspaceconfig.de\/en\/izb-biotech-news\/preclinical-efficacy-and-safety-data-for-vigenerons-innovative-approach-to-the-treatment-of-retinitis-pigmentosa-innovations-und-gruenderzentrum-biotechnologie-izb\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/p664637.webspaceconfig.de\/en\/izb-biotech-news\/preclinical-efficacy-and-safety-data-for-vigenerons-innovative-approach-to-the-treatment-of-retinitis-pigmentosa-innovations-und-gruenderzentrum-biotechnologie-izb\/#primaryimage","url":"https:\/\/p664637.webspaceconfig.de\/wp-content\/uploads\/2026\/07\/ViGeneron_Retinitis_600x383-1.jpg","contentUrl":"https:\/\/p664637.webspaceconfig.de\/wp-content\/uploads\/2026\/07\/ViGeneron_Retinitis_600x383-1.jpg","width":600,"height":383,"caption":"Retinitis pigmentosa, eine genetische Augenkrankheit. Die 3D-Abbildung zeigt die Pigmentablagerungen in der Netzhaut, die abgeschw\u00e4chten Blutgef\u00e4\u00dfe, die pigment\u00e4ren Knochenmarkstifte und das wachsartige Aussehen der optischen Scheibe."},{"@type":"BreadcrumbList","@id":"https:\/\/p664637.webspaceconfig.de\/en\/izb-biotech-news\/preclinical-efficacy-and-safety-data-for-vigenerons-innovative-approach-to-the-treatment-of-retinitis-pigmentosa-innovations-und-gruenderzentrum-biotechnologie-izb\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/p664637.webspaceconfig.de\/en\/"},{"@type":"ListItem","position":2,"name":"IZB Biotech News","item":"https:\/\/p664637.webspaceconfig.de\/izb-biotech-news\/"},{"@type":"ListItem","position":3,"name":"Preclinical efficacy and safety data for ViGeneron\u2019s innovative approach to the treatment of Retinitis Pigmentosa"}]},{"@type":"WebSite","@id":"https:\/\/p664637.webspaceconfig.de\/en\/#website","url":"https:\/\/p664637.webspaceconfig.de\/en\/","name":"IZB Innovations- und Gr\u00fcnderzentrum Biotechnologie.","description":"Der Ort f\u00fcr Biotech-Start-ups in M\u00fcnchen: Labore, B\u00fcror\u00e4ume, Netzwerk!","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/p664637.webspaceconfig.de\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/p664637.webspaceconfig.de\/en\/wp-json\/wp\/v2\/izb-biotech-news\/5796","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/p664637.webspaceconfig.de\/en\/wp-json\/wp\/v2\/izb-biotech-news"}],"about":[{"href":"https:\/\/p664637.webspaceconfig.de\/en\/wp-json\/wp\/v2\/types\/izb-biotech-news"}],"version-history":[{"count":1,"href":"https:\/\/p664637.webspaceconfig.de\/en\/wp-json\/wp\/v2\/izb-biotech-news\/5796\/revisions"}],"predecessor-version":[{"id":5797,"href":"https:\/\/p664637.webspaceconfig.de\/en\/wp-json\/wp\/v2\/izb-biotech-news\/5796\/revisions\/5797"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/p664637.webspaceconfig.de\/en\/wp-json\/wp\/v2\/media\/5795"}],"wp:attachment":[{"href":"https:\/\/p664637.webspaceconfig.de\/en\/wp-json\/wp\/v2\/media?parent=5796"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/p664637.webspaceconfig.de\/en\/wp-json\/wp\/v2\/categories?post=5796"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/p664637.webspaceconfig.de\/en\/wp-json\/wp\/v2\/tags?post=5796"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}